Jazz Pharmaceuticals (JAZZ) announced that a mid-stage study evaluating the efficacy and safety of its investigational candidate, suvecaltamide (JZP385), in adult patients with essential tremor (ET) did not meet its primary endpoint. Suvecaltamide is a highly selective and state-dependent modulator of T-type calcium channels, which play a role in the brain's control of muscle movement. Per the data readout from the phase IIb study (NCT05122650), treatment with suvecaltamide 30mg failed to achieve statistica ...